http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2725632-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_541764a1f19dce52c85cc11a6b9e4daf |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 |
| filingDate | 2019-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f9790e8f67803be57e7fd2f20d97e10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a550c85c448092cbf2ce97a0146769ba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f39ec660bf29f6b92c23b517b5572120 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ca835c292b2c7673447938e65b4dd07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_805564fca91eaec6b39d9e3072c160a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f642644a0e0ef5c119f7fa8418d3ed2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88fb4e45081084ccb2f576ab54c7eebb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83fd6978e360d13e393aa66f6e3d17d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75493a80c9b9a9db268ad4acf524c761 |
| publicationDate | 2020-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2725632-C1 |
| titleOfInvention | Pharmaceutical composition in form of capsules, having nootropic action |
| abstract | FIELD: medicine; pharmaceuticals.SUBSTANCE: invention refers to a pharmaceutical composition, namely a composition having nootropic action. Composition is capsule containing 6-[4-methoxy-3-(1H-pyrazol-1-ylmethyl)benzyl]-1,11 dimethyl-3,6,9-triazatricyclo[7.3.1.1]tetradecane-4,8 as an active substance, 12-trione - bicyclononane, and as auxiliary substances - sodium alginate, pregelatinized corn starch (PCS), sodium starch glycolate, silicon colloidal dioxide and calcium chloride, taken in certain amounts. Use of the above composition for treating and preventing memory disorders, dizziness, low concentration, emotional lability, dementia due to cerebral circulation (ischemic stroke), cerebral injuries, in Alzheimer disease in old age, to improve cognitive performance after suffering brain damage, for treating withdrawal and psychoorganic syndrome in chronic alcoholism and learning disabilities in children.EFFECT: above described nootropic composition has good solubility and stability.2 cl, 12 dwg, 15 tbl, 11 ex |
| priorityDate | 2019-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 150.